Publication
The Patients W.A.I.T. Indicator 2025: Access to Innovative Medicines in Europe
Jul 03, 2025
Download
The Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator has been running in evolving formats since 2004 and has offered a comprehensive overview of public reimbursement across over 30 countries since 2018. 

The relevance of whether an innovative molecule is included on public reimbursement lists has diminished over the years, with a rise in patient access through alternative channels and/or with restrictions. 

This year's iteration of the report retains the core availability metrics, whilst adding additional context around the positioning of the report within the broader access landscape, and greater granularity on the level of restrictions to patient access (i.e. individual patient only). These updates aim to ensure the report remains relevant in new access landscape and support the accurate use of the W.A.I.T. report. 

Information on the availability of 173 innovative medicines with central marketing authorisation between 2020 and 2023 is included. A one-year delay is applied to allow countries time to include these medicines on their public reimbursement lists, making the data accurate as of January 5, 2025.
Contact Us